DrugPatentWatch Database Preview

Details for Patent: 8,415,335

« Back to Dashboard

Which drugs does patent 8,415,335 protect, and when does it expire?

Patent 8,415,335 protects VASCEPA and is included in one NDA.

This patent has thirty patent family members in twenty countries.

Summary for Patent: 8,415,335

Title:	Methods of treating hypertriglyceridemia
Abstract:	In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.
Inventor(s):	Manku; Mehar (England, GB), Osterloh; Ian (Kent, GB), Wicker; Pierre (Mystic, CT), Braeckman; Rene (Richboro, PA), Soni; Paresh (Mystic, CT)
Assignee:	Amarin Pharmaceutical Ireland Limited (Dublin, IE)
Application Number:	13/349,157
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,415,335
Patent Claim Types: see list of patent claims	Use; Composition; Dosage form;

Drugs Protected by US Patent 8,415,335

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Amarin Pharms	VASCEPA	icosapent ethyl	CAPSULE;ORAL	202057-001	Jul 26, 2012		RX	Yes	Yes						METHOD OF REDUCING TG LEVELS IN PATIENT SUFFERING FROM SEVERE HYPERTRIGLYCERIDEMIA
Amarin Pharms	VASCEPA	icosapent ethyl	CAPSULE;ORAL	202057-002	Feb 16, 2017		RX	Yes	No						METHOD OF REDUCING TG LEVELS IN PATIENT SUFFERING FROM SEVERE HYPERTRIGLYCERIDEMIA

International Family Members for US Patent 8,415,335

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2010213899
Brazil	PI1007518
Canada	2751576
Canada	3008079
Cyprus	1114276
Denmark	2395991
European Patent Office	2395991